Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	17226
Country	Japan

Received	2015-02-25 09:53
Peer-Review Started	2015-02-26 11:37
To Make the First Decision	2015-03-26 18:03
Return for Revision	2015-03-30 13:50
Revised	2015-04-06 10:01
Second Decision	2015-08-03 19:16
Accepted by Journal Editor-in-Chief	2015-08-06 09:34
Accepted by Company Editor-in-Chief	2015-08-28 09:52
Articles in Press	2015-08-28 11:00
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-10-22 21:26
Publish the Manuscript Online	2015-11-17 08:51

ISSN	1948-5204 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Topic Highlights
Article Title	Clinical significance of MET in gastric cancer
Manuscript Source	Invited Manuscript
All Author List	Mikito Inokuchi, Sho Otsuki, Yoshitaka Fujimori, Yuya Sato, Masatoshi Nakagawa and Kazuyuki Kojima
Funding Agency and Grant Number
Corresponding Author	Mikito Inokuchi, MD, PhD, Department of Gastrointestinal Surgery, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. m-inokuchi.srg2@tmd.ac.jp
Key Words	MET; Gastric cancer; Genomic amplification; Immunohistochemistry; Clinical trial
Core Tip	MET protein overexpression or MET gene amplification was associated with tumor progression and survival in gastric cancer (GC), although the definition of MET overexpression remains to be standardized. In preclinical studies, MET antibodies or small-molecule MET inhibitors suppressed cell proliferation and tumor progression in MET-amplified GC cells. Therefore, MET-targeting therapy is promising, and MET overexpression might be a useful biomarker of the response to chemotherapy inhibiting MET. Some clinical trials of MET inhibitors were conducted in metastatic GC, but sufficient benefits have not been demonstrated yet.
Publish Date	2015-11-17 08:51
Citation	Inokuchi M, Otsuki S, Fujimori Y, Sato Y, Nakagawa M, Kojima K. Clinical significance of MET in gastric cancer. World J Gastrointest Oncol 2015; 7(11): 317-327
URL	http://www.wjgnet.com/1948-5204/full/v7/i11/317.htm
DOI	http://dx.doi.org/10.4251/wjgo.v7.i11.317

Full Article (PDF)	WJGO-7-317.pdf
Full Article (Word)	WJGO-7-317.doc
Manuscript File	17226-Review.docx
Answering Reviewers	17226-Answering reviewers.pdf
Audio Core Tip	17226-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	17226-Conflict-of-interest statement.pdf
Copyright License Agreement	17226-Copyright assignment.pdf
Peer-review Report	17226-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	17226-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	17226-Scientific misconduct check.pdf
Scientific Editor Work List	17226-Scientific editor work list.pdf